Vimentin—a new prognostic parameter in breast carcinoma?

This report describes a positive relationship between vimentin expression in infiltrating ductal breast carcinoma, and high tumour growth fraction. Vimentin expression is potentially a predictor of aggressive behaviour, and such carcinomas may benefit from early adjuvant therapy.

[1]  A. Gown,et al.  Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. , 1985, American journal of clinical pathology.

[2]  W Heidenreich,et al.  The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma , 1987, Cancer.

[3]  I. Damjanov.  Antibodies to intermediate filaments and histogenesis. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[4]  M. M. McCrate,et al.  Prediction of early course of breast carcinoma by thymidine labeling , 1983, Cancer.

[5]  A. Leong,et al.  Antigen preservation in microwave‐irradiated tissues: A comparison with formaldehyde fixation , 1988, The Journal of pathology.

[6]  K. Weber,et al.  Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[7]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[8]  A. Leong,et al.  Microwave irradiation as a form of fixation for light and electron microscopy , 1985, The Journal of pathology.

[9]  M. Tubiana,et al.  Kinetic parameters and the course of the disease in breast cancer , 1981, Cancer.

[10]  A. Leong,et al.  An Evaluation of Potentially Suitable Fixatives for Immunoperoxidase Staining of Estrogen Receptors in Imprints and Frozen Sections of Breast Carcinoma , 1988, Pathology.

[11]  A. Leong,et al.  The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining , 1989, The Journal of pathology.

[12]  K. Weber,et al.  Monoclonal antibodies specific for vimentin. , 1984, European journal of cell biology.

[13]  W. Bezwoda,et al.  Breast cancer in men. Clinical features, hormone receptor status, and response to therapy , 1987, Cancer.

[14]  L. Bobrow,et al.  Monoclonal antibody to cytokeratin for use in routine histopathology. , 1984, Journal of clinical pathology.

[15]  M. Tubiana,et al.  The long‐term prognostic significance of the thymidine labelling index in breast cancer , 1984, International journal of cancer.

[16]  W. Franklin,et al.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast , 1987, Cancer.

[17]  J. Meyer.  Cell kinetic measurements of human tumors. , 1982, Human pathology.

[18]  R. Silvestrini,et al.  Cell proliferation and its relationship to clinical features and relapse in breast cancers , 1981 .

[19]  R. Warnke,et al.  Quantitation and estimation of lymphocyte subsets in tissue sections. Comparison with flow cytometry. , 1987, American journal of clinical pathology.

[20]  P. Rosen,et al.  Estrogen receptor protein in breast cancer as a predictor of recurrence , 1981, Cancer.

[21]  H Stein,et al.  Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. , 1986, Journal of clinical pathology.

[22]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[23]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[24]  N. Lemoine,et al.  Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables , 1987, The Journal of pathology.

[25]  S. Hirohashi,et al.  Expression of Vimentin in Surgically Resected Adenocarcinomas and Large Cell Carcinomas of Lung , 1986, The American journal of surgical pathology.

[26]  M. Leader,et al.  Vimentin: an evaluation of its role as a tumour marker , 1987, Histopathology.

[27]  I. Ellis,et al.  Immunocytochemical investigation of intermediate filament proteins and epithelial membrane antigen in spindle cell tumours of the breast , 1988, The Journal of pathology.

[28]  D. Dahl.  The vimentin‐GFA protein transition in rat neuroglia cytoskeleton occurs at the time of myelination , 1981, Journal of neuroscience research.

[29]  A. Leong,et al.  Rapid immunoperoxidase staining of lymphocyte antigens using microwave irradiation , 1986, The Journal of pathology.

[30]  M. Daidone,et al.  Cell kinetics as a prognostic marker in node‐negative breast cancer , 1985, Cancer.

[31]  N. Azumi,et al.  The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. , 1987, American journal of clinical pathology.

[32]  J. Milios,et al.  Atypical fibroxanthoma of the skin: a clinicopathological and immunohistochemical study and a discussion of its histogenesis , 1987, Histopathology.

[33]  M. Feldstein,et al.  The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer , 1980, Cancer.

[34]  W. Franke,et al.  Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. , 1981, The American journal of pathology.

[35]  J. Meyer,et al.  Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. , 1979, Cancer research.

[36]  V. Gould.  Histogenesis and differentiation: a re-evaluation of these concepts as criteria for the classification of tumors. , 1986, Human pathology.

[37]  J. Vegelius,et al.  Analysis of reproducibility of subjective grading systems for breast carcinoma. , 1979, Journal of clinical pathology.